We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.52%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$439M
AUM Growth
+$75.3M
Cap. Flow
-$56.5M
Cap. Flow %
-12.86%
Top 10 Hldgs %
60.79%
Holding
73
New
15
Increased
16
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$12M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$10.9M
4
ABBV icon
AbbVie
ABBV
+$10.8M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.29M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$15M
2
LH icon
Labcorp
LH
+$12.9M
3
ICLR icon
Icon
ICLR
+$7.95M
4
HAE icon
Haemonetics
HAE
+$7.86M
5
CI icon
Cigna
CI
+$7.76M

Sector Composition

Rank Sector Weight
1 Healthcare 60.22%
2 Industrials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVC
51
DELISTED
Invacare Corporation
IVC
$323K 0.07%
1,146,068
-228,772
-17% -$1.67M
BAX icon
52
Baxter International
BAX
$14B
– –
-25,059
Closed -$2.02M
ELV icon
53
Elevance Health
ELV
$84.9B
– –
-11,941
Closed -$4.56M
FATE icon
54
Fate Therapeutics
FATE
$290M
– –
-51,031
Closed -$4.43M
FBRX icon
55
Forte Biosciences
FBRX
$1.57B
– –
-2,135
Closed -$1.79M
HAE icon
56
Haemonetics
HAE
$3.86B
– –
-117,904
Closed -$7.86M
PNTG icon
57
Pennant Group
PNTG
$1.36B
– –
-47,475
Closed -$1.94M
REGN icon
58
Regeneron Pharmaceuticals
REGN
$79.5B
– –
-5,563
Closed -$3.11M
SPRY icon
59
ARS Pharmaceuticals
SPRY
$551M
– –
-139,124
Closed -$4.3M
SRPT icon
60
Sarepta Therapeutics
SRPT
$1.77B
– –
-28,625
Closed -$2.23M
TFX icon
61
Teleflex
TFX
$6.15B
– –
-7,501
Closed -$3.01M
TMO icon
62
Thermo Fisher Scientific
TMO
$214B
– –
-29,679
Closed -$15M
VRTX icon
63
Vertex Pharmaceuticals
VRTX
$123B
– –
-7,553
Closed -$1.52M
XFOR icon
64
X4 Pharmaceuticals
XFOR
$393M
– –
-2,366
Closed -$461K
CALT
65
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-144,393
Closed -$4.25M
MDVL
66
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
– –
-5,844
Closed -$3.58M
CANO
67
DELISTED
Cano Health, Inc.
CANO
– –
-620
Closed -$750K
PRVB
68
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-82,960
Closed -$699K
EAR
69
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-9,674
Closed -$7.72M
TRIL
70
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-600,788
Closed -$7.02M
1 2
3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Endurant Capital Management held 73 positions worth $439M, up 21% from $364M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Endurant Capital Management withdrew a net $56.5M in Q3 2021, closing 21 positions and reducing 20 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 80% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in AptarGroup worth $6.11M.

  • Endurant Capital Management's largest Q3 2021 buy was AptarGroup: 51,191 shares worth $6.11M.
  • Endurant Capital Management added most to Humana in Q3 2021, an estimated $12M increase.
  • Endurant Capital Management's biggest Q3 2021 reduction was Labcorp, cutting an estimated $12.9M.
  • Endurant Capital Management fully exited Thermo Fisher Scientific in Q3 2021, selling an estimated $15M.
  • Endurant Capital Management's ten largest holdings make up 61% of its $439M portfolio in Q3 2021.
  • Endurant Capital Management opened 15 new positions and closed 21 in Q3 2021.
  • Endurant Capital Management's portfolio value rose 21% quarter-over-quarter to $439M.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.